LLY

981.29

-2.24%↓

JNJ

239.53

-2.3%↓

ABBV

232.07

-1.66%↓

NVS

160.95

-2.49%↓

AZN

197.36

-2.11%↓

LLY

981.29

-2.24%↓

JNJ

239.53

-2.3%↓

ABBV

232.07

-1.66%↓

NVS

160.95

-2.49%↓

AZN

197.36

-2.11%↓

LLY

981.29

-2.24%↓

JNJ

239.53

-2.3%↓

ABBV

232.07

-1.66%↓

NVS

160.95

-2.49%↓

AZN

197.36

-2.11%↓

LLY

981.29

-2.24%↓

JNJ

239.53

-2.3%↓

ABBV

232.07

-1.66%↓

NVS

160.95

-2.49%↓

AZN

197.36

-2.11%↓

LLY

981.29

-2.24%↓

JNJ

239.53

-2.3%↓

ABBV

232.07

-1.66%↓

NVS

160.95

-2.49%↓

AZN

197.36

-2.11%↓

Search

Bio-Techne Corp

Gesloten

SectorGezondheidszorg

55.85 -3.44

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

55.29

Max

58.61

Belangrijke statistieken

By Trading Economics

Inkomsten

-176K

38M

Verkoop

9.3M

296M

K/W

Sectorgemiddelde

109.094

66.845

Dividendrendement

0.54

Winstmarge

12.846

Werknemers

3,100

EBITDA

-135K

78M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+27.48% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

0.54%

2.25%

Volgende Winsten

6 mei 2026

Volgende dividenddatum

29 mei 2026

Volgende Ex Dividend datum

18 mei 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-1.1B

9B

Vorige openingsprijs

59.29

Vorige sluitingsprijs

55.85

Nieuwssentiment

By Acuity

37%

63%

118 / 351 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bullish Evidence

Bio-Techne Corp Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

7 nov 2025, 22:36 UTC

Winsten

McDonald's Stock Challenged By a Tougher Economy, Analyst Says. Plus, Marriott, Snowflake, and More. -- Barrons.com

Peer Vergelijking

Prijswijziging

Bio-Techne Corp Prognose

Koersdoel

By TipRanks

27.48% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 73.75 USD  27.48%

Hoogste 80 USD

Laagste 65 USD

Gebaseerd op 9 Wall Street-analisten die 12-maands prijsdoelen bieden voor Bio-Techne Corp - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

9 ratings

6

Buy

3

Hold

0

Sell

Technische score

By Trading Central

49.67 / 50.24Steun & Weerstand

Korte Termijn

Weak Bullish Evidence

Gemiddeld Termijn

Weak Bullish Evidence

Lange Termijn

Strong Bearish Evidence

Sentiment

By Acuity

118 / 351 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Bio-Techne Corp

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company has strategic partnership with ALZpath, Inc. to accelerate breakthroughs in neurodegenerative disease research and treatment, including Alzheimer's disease. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
help-icon Live chat